Omics Gaucher Study: Multiomic Approach

N/AActive Not RecruitingNCT05526664

CENTOGENE GmbH Rostock25 enrolled

Overview

The study aims to investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Gaucher disease is one of the most common lysosomal storage disorders (LSD) and is an autosomal recessive inherited disorder, primed by mutation in the GBA1 gene which leads to a deficiency in β-glucocerebrosidase (GCase) activity and accumulation of its substrate glucosylceramide (GluCer)/-sphingosine (GluSph). The macrophages are the main cell type exhibiting a Gaucher disease phenotype. The large accumulation of GluCer and to a lesser extent that of GluSph lead to dysfunction in organs such as spleen, liver, bone marrow, and lungs. However, a validated, reproducible, and broadly applicable tool to classify Gaucher Disease at any stage of the disease is still missing. The development of new technologies, such as genomic analysis by next generation sequencing (NGS) and other "omics technologies," has advanced the molecular understanding and diagnosis of Rare Diseases The current study will analyze the transcriptional and metabolomic profiles in blood, plasma and isolated monocytes from Gaucher patients and healthy controls with the aim to compare these profiles and to define how much a patient profile differs from a healthy one.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Gaucher Disease

Interventions

Genetic testing and Omics analysisOTHER

Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Gaucher Type 1 participants: * Informed consent * The participant is older than 18 years old * The participant was diagnosed with Gaucher Type 1 disease Gaucher Type 3 participants: * Informed consent * The participant is older than 18 years old * The participant was diagnosed with Gaucher type 3 disease Healthy participants: * Informed consent * The participant is older than 18 years old * Healthy participants Exclusion Criteria: Gaucher Type I participants: * The participant had any other clinically significant disease * The participant had a recent (within 14 days) acute infection and/or vaccination Gaucher Type 3 participants: * Diagnosis of a significant CNS disease or cardiovascular disease other than Gaucher type 3 * The participant had a recent (within 14 days) acute infection and/or vaccination Healthy participants: * The participant had a recent (within 14 days) acute infection and/or vaccination

Locations (1)

UKE

Hamburg, Germany

Outcomes

Primary Outcomes

OMICS DATA

investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.